Torrado Durán, Juan José

Profile Picture
First Name
Juan José
Last Name
Torrado Durán
Universidad Complutense de Madrid
Faculty / Institute
Farmacia Galénica y Tecnología Alimentaria
Farmacia y Tecnología Farmaceútica
UCM identifierORCIDScopus Author IDWeb of Science ResearcherIDDialnet IDGoogle Scholar ID

Search Results

Now showing 1 - 10 of 18
  • Publication
    Evaluating the Potential of Ursolic Acid as Bioproduct for Cutaneous and Visceral Leishmaniasis
    (MDPI, 2020-03-19) Bilbao Ramos, Pablo Estanislao; Serrano López, Dolores Remedios; Ruiz Saldaña, Helga Karina; Torrado Durán, Juan José; Bolás Fernández, Francisco; Dea Ayuela, María Auxiliadora
    Leishmaniasis affects around 12 million people worldwide and is estimated to cause the ninth-largest disease burden. There are three main forms of the disease, visceral (VL), cutaneous (CL), and mucocutaneous (MCL), leading to more than one million new cases every year and several thousand deaths. Current treatments based on chemically synthesized molecules are far from ideal. In this study, we have tested the in vitro and in vivo efficacy of ursolic acid (UA), a multifunctional triterpenoid with well-known antitumoral, antioxidant, and antimicrobial effects on different Leishmania strains. The in vitro antileishmanial activity against the intracellular forms was six and three-fold higher compared to extracellular forms of L. amazonensis and L. infantum, respectively. UA also showed to be a potent antileishmanial drug against both VL and CL manifestations of the disease in experimental models. UA parenterally administered at 5 mg/kg for seven days significantly reduced the parasite burden in liver and spleen not only in murine acute infection but also in a chronic-infection model against L. infantum. In addition, UA ointment (0.2%) topically administered for four weeks diminished (50%) lesion size progression in a chronic infection model of CL caused by L. amazonensis, which was much greater than the effect of UA formulated as an O/W emulsion. UA played a key role in the immunological response modulating the Th1 response. The exposure of Leishmania-infected macrophages to UA led to a significant different production in the cytokine levels depending on the Leishmania strain causing the infection. In conclusion, UA can be a promising therapy against both CL and VL.
  • Publication
    Tuning the Transdermal Delivery of Hydroquinone upon Formulation with Novel Permeation Enhancers
    (MDPI, 2019-04-04) Serrano, Dolores R.; Gordo, María José; Matji, Antonio; González, Salvador; Lalatsa, Aikaterini; Torrado Durán, Juan José
    Hydroquinone (HQ) is an anti-hyperpigmentation agent with poor physicochemical stability. HQ formulations are currently elaborated by compounding in local pharmacies. Variability in the characteristics of HQ topical formulations can lead to remarkable di_erences in terms of their stability, e_cacy, and toxicity. Four di_erent semisolid O/Wformulations with 5% HQ were prepared using: (i) Beeler´s base plus antioxidants (F1), (ii) Beeler´s base and dimethyl isosorbide (DMI) as solubiliser (F2), (iii) olive oil and DMI (F3), and (iv) Nourivan®, a skin-moisturising and antioxidant base, along with DMI (F4). Amongst the four formulations, F3 showed the greatest physicochemical stability with less tendency to coalescence but with marked chromatic aberrations. An inverse correlation was established by multivariate analysis between the mean droplet size in volume and the steady-state flux, which explains why F3, with the smallest droplet size and the most hydrophobic excipients, exhibited the highest permeation across both types of membranes with enhancement ratios of 2.26 and 5.67-fold across Strat-M® and mouse skin, respectively, compared to F1. It is crucial to understand how the HQ is formulated, bearing in mind that the use of di_erent excipients can tune the transdermal delivery of HQ significantly.
  • Publication
    Creación de nuevo recurso educativo virtual para estudiantes de grado en Farmacia
    (2020-07-07) Torrado Durán, Susana; Ballesteros Papantonakis, María de la Paloma; Torrado Durán, Juan José; Torre Iglesias, Paloma Marina de la; Torrado Durán, Santiago; Álvarez Álvarez, Covadonga; Martínez Caballero, María Aranzazu; Martínez Caballero, Marta; Torrado Durán, Guillermo; Serrano López, Dolores Remedios; Ares Lombán, Irma; Torrado Salmerón, Carlos Felix; Rodríguez Torrado, Marta; Fernández Gutiérrez, Jesús Miguel; Rodríguez Torrado, David; Notivoli Díez, Pablo; Franco Gil, María Elvira
  • Publication
    Creación de nuevos recursos educativos virtuales para estudiantes de grado en Farmacia
    (2022) Torrado Durán, Susana; Ballesteros Papantonakis, Paloma; Torrado Durán, Juan José; Álvarez Álvarez, Covadonga; Torrado Durán, Santiago; Martínez Caballero, Marta; Torrado Durán, Guillermo; Martínez Caballero, María Aranzazu; Franco Gil, Elvira; Sastre Barbas, Almudena; Rodríguez Torrado, Marta; Torrado Salmerón, Carlos Félix; De la Torre Iglesias, Paloma; Rodríguez Torrado, David; Ares Lombán, Irma; Fernández Gutierrez, Jesús Miguel
  • Publication
    Targeting lung macrophages for fungal and parasitic pulmonary infections with innovative amphotericin B dry powder inhalers
    (Elsevier, 2023-03-25) de Pablo, E; O'Connell, Peter; Fernández García, Raquel; Marchand, Sandrine; Chauzy, A.; Tewes, F; Dea Ayuela, María Auxiliadora; Kumar, D.; Bolás Fernández, Francisco; Ballesteros Papantonakis, Paloma; Torrado Durán, Juan José; Healy, Anne Marie; Serrano López, Dolores Remedios
    The incidence of fungal pulmonary infections is known to be on the increase, and yet there is an alarming gap in terms of marketed antifungal therapies that are available for pulmonary administration. Amphotericin B (AmB) is a highly efficient broad-spectrum antifungal only marketed as an intravenous formulation. Based on the lack of effective antifungal and antiparasitic pulmonary treatments, the aim of this study was to develop a carbohydrate-based AmB dry powder inhaler (DPI) formulation, prepared by spray drying. Amorphous AmB microparticles were developed by combining 39.7% AmB with 39.7% γ-cyclodextrin, 8.1% mannose and 12.5% leucine. An increase in the mannose concentration from 8.1 to 29.8%, led to partial drug crystallisation. Both formulations showed good in vitro lung deposition characteristics (80% FPF< 5 µm and MMAD < 3 µm) at different air flow rates (60 and 30 L/min) when used with a DPI, but also during nebulisation upon reconstitution in water.
  • Publication
    One and Two-Step In Vitro-In Vivo Correlations Based on USP IV Dynamic Dissolution Applied to Four Sodium Montelukast Products
    (MDPI, 2021-05-11) Prieto Escolar, Mercedes; Torrado Durán, Juan José; Álvarez Álvarez, Covadonga; Ruiz Picazo, Alejandro; Simón-Vázquez, Marta; Govantes, Carlos; Frias, Jesús; García Arieta, Alfredo; González Álvarez, Isabel; Bermejo, Marival
    Montelukast is a weak acid drug characterized by its low solubility in the range of pH 1.2 to 4.5, which may lead to dissolution-limited absorption. The aim of this paper is to develop an in vivo predictive dissolution method for montelukast and to check its performance by establishing a level-A in vitro-in vivo correlation (IVIVC). During the development of a generic film-coated tablet formulation, two clinical trials were done with three different experimental formulations to achieve a similar formulation to the reference one. A dissolution test procedure with a flow-through cell (USP IV) was used to predict the in vivo absorption behavior. The method proposed is based on a flow rate of 5 mL/min and changes of pH mediums from 1.2 to 4.5 and then to 6.8 with standard pharmacopoeia buffers. In order to improve the dissolution of montelukast, sodium dodecyl sulfate was added to the 4.5 and 6.8 pH mediums. Dissolution profiles in from the new method were used to develop a level-A IVIVC. One-step level-A IVIVC was developed from dissolution profiles and fractions absorbed obtained by the Loo–Riegelman method. Time scaling with Levy’s plot was necessary to achieve a linear IVIVC. One-step differential equation-based IVIVC was also developed with a time-scaling function. The developed method showed similar results to a previously proposed biopredictive method for montelukast, and the added value showed the ability to discriminate among different release rates in vitro, matching the in vivo clinical bioequivalence results.
  • Publication
    Antifungal and Antiparasitic Drug Delivery
    (MDPI, 2020-04-04) Torrado Durán, Juan José; Serrano López, Dolores Remedios; Capilla, Javier
    Fungal and parasitic diseases affect more than a billion people across the globe, one-sixth of the world’s population, mostly located in developing countries. The lack of effective and safer treatments combined with a deficient diagnosis lead to serious chronic illness or even death. There is a mismatch between the rate of drug resistance and the development of new medicines. Formulation of antifungal and antiparasitic drugs adapted to different administration routes is challenging, bearing in mind their poor water solubility, which limits their bioavailability and efficacy. Hence, there is an unmet clinical need to develop vaccines and novel formulations and drug delivery strategies that can improve the bioavailability and therapeutic effect by enhancing their dissolution, increasing their chemical potency, stabilising the drug and targeting high concentration of drug to the infection sites. This Editorial regards the ten research contributions presented in the Special Issue “Antifungal and Antiparasitic Drug Delivery”.
  • Publication
    Nueva estrategia didáctica para fomentar la participación del alumnado en el proceso de aprendizaje en el ámbito de la tecnología farmacéutica (continuación)
    (2017-06-30) Torrado Durán, Susana; Torre Iglesias, Paloma; Torrado Durán, Juan José; Torrado Durán, Santiago; Ballesteros Papantonakis, Paloma; Álvarez Álvarez, Covadonga; Franco Gil, Elvira; Torrado Durán, Guillermo; Serrano López, Dolores Remedios; Martin Erdocia, Izaskun; Ares Lombán, Irma; Martínez Caballero, María Aranzazu; Martínez Caballero, Marta; López Sánchez, Alicia
  • Publication
    Toxicology of Blister Agents: Is Melatonin a Potential Therapeutic Option?
    (MDPI, 2021-04-10) Romero Martínez, Manuel Alejandro; Ramos Alonso, Eva; López Muñoz, Francisco; Ríos, Cristóbal de los; Egea, Javier; Gil Martín, Emilio; Pita Pita, Rene; Torrado Durán, Juan José; Serrano López, Dolores Remedios; Juberias, Antonio
    Blister or vesicant chemical warfare agents (CWAs) have been widely used in different military conflicts, including World War I and the Iran-Iraq War. However, their mechanism of action is not fully understood. Sulfur and nitrogen mustard exert toxic effects not only through the alkylation of thiol-bearing macromolecules, such as DNA and proteins, but also produce free radicals that can develop direct toxic effects in target organs such as the eyes, skin, and respiratory system. The lack of effective treatments against vesicant CWAs-induced injury makes us consider, in this complex scenario, the use and development of melatonin-based therapeutic strategies. This multifunctional indoleamine could facilitate neutralization of the oxidative stress, modulate the inflammatory response, and prevent the DNA damage, as well as the long-term health consequences mediated by vesicant CWAs-induced epigenetic mechanisms. In this context, it would be essential to develop new galenic formulations for the use of orally and/or topically applied melatonin for the prophylaxis against vesicant CWAs, as well as the development of post-exposure treatments in the near future.
  • Publication
    Permeability Characteristics of a New Antifungal Topical Amphotericin B Formulation with γ-Cyclodextrins
    (MDPI, 2018-12-18) López Castillo, Carmen; Rodríguez Fernández, Carmina; Córdoba Díaz, Manuel; Torrado Durán, Juan José
    Amphotericin B is a low soluble broad-spectrum antifungal agent. Cyclodextrins can be added to amphotericin formulations to enhance both their solubility and antifungal properties. Semisolid amphotericin formulations containing gamma cyclodextrin (AGCD) were prepared and compared with two reference formulations—one of them without any solubility enhancer (A) and the other with DMSO (ADMSO). Rheological, the permeability through hairless mouse skin and antifungal characteristics of the different formulations were evaluated. All three semisolid formulations show low thixotropy characteristics. ADMSO was the formulation with the least consistency, lowest viscosity, and greatest extensibility. The AGCD formulation had the opposite behavior and had both the greatest consistency and viscosity and the lowest extensibility. The lowest permeability was obtained with the reference A formulation while both AGCD and ADMSO had a similar permeability enhancement. According to the antimicrobial in vitro efficacy trials, the AGCD formulation showed 45–60% more activity than the reference A formulation. It can be concluded that γ-cyclodextrin is a useful excipient to improve the solubility, permeability, and antifungal activity of amphotericin B in semisolid topical formulations.